logo
Share SHARE
FONT-SIZE Plus   Neg

BioMarin Pharma: FDA Accepts Vimizim BLA And Grants Priority Review Designation

BioMarin Pharmaceutical Inc. (BMRN) announced that the U.S. Food and Drug Administration or FDA has accepted for review the Biologics License Application or BLA for Vimizim (BMN-110, elosulfase alfa), an enzyme replacement therapy under evaluation for the treatment of patients with the rare lysosomal storage disorder Mucopolysaccharidosis Type IVA or MPS IVA, also called Morquio A Syndrome.

The company said that the FDA has granted priority review designation to Vimizim, which is granted to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. During the initial review of the application, the FDA requested additional Chemistry, Manufacturing and Controls or CMC information.

The company provided the information as requested, and the FDA designated it as a major amendment to the application thus extending the PDUFA action date by three months. The extended PDUFA action date is February 28, 2014.

In the FDA's filing communication, the Agency informed the company that it is currently planning to hold an advisory committee meeting to discuss the application. No date has been set for this meeting.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Data storage firm NetApp Inc. (NTAP) Monday said Chief Executive Officer and Chairman Tom Georgens has stepped down. The company has appointed George Kurian, executive vice-president of product operations, as the new CEO. Georgens' resignation comes just couple of weeks after NetApp reported a fourth-quarter... Apparel maker PVH Corp. said Monday after the markets closed that its first quarter profit rose sharply from last year, when results were weighed down by debt modification and extinguishment costs. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue. Walt Disney said its Chief Financial Officer James Rasulo will step down effective June 30, after five years in that position.
comments powered by Disqus
RELATED NEWS
Trade BMRN now with 
Follow RTT